Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4780406 | 1.00 | SLC1A2 (0.47) | SLC1A2AKR1C3AKR1C1MEN1BLM | |
| SCHEMBL5203561 | 1.00 | SLC1A2 (0.47) | SLC1A2AKR1C3AKR1C1MEN1BLM | |
| SCHEMBL199463 | 1.00 | SLC1A2 (0.47) | SLC1A2AKR1C3AKR1C1MEN1BLM | |
| SCHEMBL199462 | 1.00 | SLC1A2 (0.47) | SLC1A2AKR1C3AKR1C1MEN1BLM | |
| SCHEMBL199461 | 1.00 | SLC1A2 (0.47) | SLC1A2AKR1C3AKR1C1MEN1BLM | |
| Hydrochloric Acid SCHEMBL2297672 | 0.98 | SLC1A2 (0.46) | SLC1A2AKR1C3AKR1C1MEN1BLM | |
| Hydrochloric Acid SCHEMBL2297675 | 0.98 | SLC1A2 (0.46) | SLC1A2AKR1C3AKR1C1MEN1BLM | |
| SCHEMBL851578 | 0.89 | MEN1 (0.50) | SLC1A2MEN1BLMKMT2A | |
| SCHEMBL16056887 | 0.89 | MEN1 (0.50) | SLC1A2MEN1BLMKMT2A | |
| SCHEMBL4074609 | 0.89 | MEN1 (0.50) | SLC1A2MEN1BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | claimed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | claimed |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-04-13 | — | — | US | claimed |
| US-20220372022-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-11-24 | — | — | US | claimed |
| EP-1214345-B1 | AGENTS FOR TREATING HUMAN DISEASES, ESPECIALLY FOR TREATING TUMORS SUCH AS COLONIC CANCERS AND MELANOMAS OR FOR REGENERATING TISSUE AND PROMOTING HAIR GROWTH | MAX DELBRUECK CENTRUM (DE) | 2004-12-29 | — | — | EP | claimed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250388601-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12358928-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | disclosed |
| US-5883077-A | PEPTIDES ALDEHYDE ANALOGUES | CORVAS INTERNATIONAL, INC. (US) | 1999-03-16 | — | — | US | disclosed |
| WO-1999006434-A1 | 4-AMINO-PHENYLALANINE TYPE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| US-5739112-A | ANTICOAGULANTS | CORVAS INTERNATIONAL, INC. (US) | 1998-04-14 | — | — | US | disclosed |
| WO-1998008815-A1 | SUBSTITUTED CYCLIC AMINE METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| WO-1996013266-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1996-05-09 | — | — | WO | disclosed |
| EP-0675899-A4 | NOVEL INHIBITORS OF FACTOR Xa. | CORVAS INT INC (US) | 1996-01-24 | — | — | EP | disclosed |
| EP-0675899-A1 | NOVEL INHIBITORS OF FACTOR Xa | CORVAS INTERNATIONAL, INC. (US) | 1995-10-11 | — | — | EP | disclosed |
| WO-1994013693-A1 | NOVEL INHIBITORS OF FACTOR Xa | CORVAS INTERNATIONAL, INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | SLC1A2 2114/4885AKR1C3 4666/4885AKR1C1 4467/4885 |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | SLC1A2 78/4885AKR1C3 4010/4885AKR1C1 4270/4885 |
| US-20250388601-A1 | Compounds, Compositions and Methods | AURKC, WEE2, ERBB2 | SLC1A2 3321/4885AKR1C3 703/4885AKR1C1 843/4885 |
| US-12358928-B2 | Compounds, compositions and methods | PIK3CA, PLK1, PIK3CB | SLC1A2 4794/4885AKR1C3 3369/4885AKR1C1 3871/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | SLC1A2 2316/4885AKR1C3 2672/4885AKR1C1 3127/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | SLC1A2 1617/4885AKR1C3 2443/4885AKR1C1 2370/4885 |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | TST, ABAT, AADAC | SLC1A2 1423/4885AKR1C3 2947/4885AKR1C1 2811/4885 |
| US-20220372022-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | DNPEP, NPEPPS, PAM | SLC1A2 2114/4885AKR1C3 4666/4885AKR1C1 4467/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | SLC1A2 271/4885AKR1C3 2222/4885AKR1C1 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.